Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

Canadian Cancer Trials Group EN.7 -- Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

The Canadian Cancer Trials Group EN.7 trial (PORTEC-3) was closed to on December 20, 2013 after reaching its accrual goal of 970 patients.

_________________

Canadian Cancer Trials Group IND.207 -- A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma

As per protocol, Canadian Cancer Trials Group IND.207 was closed to accrual on January, 9, 2014.

_________________

Canadian Cancer Trials Group IND.205 -- A Phase II Study of PX-866 in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

Canadian Cancer Trials Group IND.205 Part B was closed to accrual today, January 10, 2014. Part A was closed to accrual in November 2012. At that time, IND.205 Part B was opened, which looked at the efficacy of adding PX-866 to abiraterone/prednisone for patients who have just had PSA progression on abiraterone/prednisone.


Thank you to all participating sites, staff and patients for your contributions to these studies.